Topic: cardiovascular disease


Sanifit is breaking the mold in its native country: Back in June, it raised a massive €55.2 million ($62.9 million) series D round, smashing Spanish biotech VC records and ranking as one of the biggest life sciences raises in Europe for the year.

Anthos Therapeutics

Launched in February with $250 million and a midphase heart disease drug from Novartis, Anthos’ sizable war chest means it can run large cardiovascular studies that are often beyond the reach of young biotech companies.